News & Insight

News
A network approach reveals roles for cancer stem cells in cancer promotion
Q&A with Professor Allan Balmain and Dr Mark Taylor on new findings from the PROMINENT team, tackling our Normal Phenotypes challenge
We talked to team PROMINENT members Professor Allan Balmain and Dr Mark Taylor from the University of California San Francisco about their latest paper ‘Stem-cell states converge in multi-stage cutaneous squamous cell carcinoma development…
Read the full article

Latest

News
Global team uncovers genomic secrets behind varied incidence in kidney cancer rates
In a landmark paper published today (1 May, 2024) by the Mutographs team in Nature, they identify new mutational signatures at play in the…
News
Five new teams selected to take on cancer’s toughest challenges
Today we’re excited to announce the five new global teams that have been selected to each receive up to $25m in Cancer Grand Challenges funding over…
Blog
Embedding patient advocacy within a discovery science initiative
As we look towards announcing our new teams on 6 March, we reflect with former members of the Cancer Grand Challenges Advocacy Panel on the role the…
Blog
A holistic approach to cancer research: bringing future research leaders together with patient advocates
Last month we held our annual Future Leaders Conference in Lisbon. As well as being a time for early career researchers from across our funded teams…

News and insight archive

Format
Choose
Team
Choose
Tags
Choose
Mutographs collaborators
News
Unexpected findings from the Mutographs team: huge global variation in oesophageal cancer incidence is not due to a unique pattern of DNA damage
Oesophageal squamous cell carcinoma (ESCC) is the most common type of oesophageal cancer – a disease that affected more than 600,000 people worldwide last year*. Incidence of the disease varies dramatically around the…
Mutographs
News
New findings, old ideas: reviving a decades old view on the causes of cancer
Surprising discoveries from the Mutographs team challenge the classical view that all carcinogens directly cause mutations and suggest that non-mutagenic agents play a greater role in tumour promotion than originally…
Defy the impossible
News
Discover: a year of scientific creativity
Launching Discover: a year of scientific creativity – our annual progress magazine showcasing the power of global team science. Discover celebrates how our teams are coming together, thinking differently and driving…
Kevin quote
News
The rules (not the exceptions) of cancer tissue specificity
The SPECIFICANCER team delves deeper into the biological laws that govern tissue specificity in cancer and reveals intricate webs of genetic interactions. This story first featured in our annual progress magazine - …
IMAXT
News
Genes in space: the future of biology is spatial
A new expansion sequencing toolbox and analysis platform from the IMAXT team reveals hidden truths in biology by creating detailed nanoscale-resolution genomic maps. This story first featured in our annual progress…
Rosetta
News
Uncharted territory: metabolic tumour maps reveal new therapeutic avenues
A deeper understanding of the metabolic changes during tumour development could radically change clinical decision-making and unlock opportunities to intervene across the entire patient journey. This story first…
Storming
News
Matrix remodelling in the transformation from inflammation to malignancy   
Chronic inflammation is directly linked to up to 25% of cancer deaths worldwide. Could reprogramming of the inflamed microenvironment prevent, slow or even revert the cascade of inflammation to malignancy?  This story…
OPTIMISTICC
News
Hidden treasure: do the clues to preventing and detecting colorectal cancer lie in the microbiome?
The OPTIMISTICC team identifies microbiological signatures which may make colorectal cancer screening available for all. This story first featured in our annual progress magazine - Discover: a year of scientific…
P
News
A step closer to distinguishing harmless from invasive breast lesions 
New findings from our PRECISION team define clinical criteria that may distinguish between patients with harmless breast carcinoma from those with a higher risk of invasive cancer. This story first featured in our…